Related Experiment Video
Updated: Jan 23, 2026

Induction and Validation of Cellular Senescence in Primary Human Cells
Published on: June 20, 2018
MHY2233 Attenuates Replicative Cellular Senescence in Human Endothelial Progenitor Cells via SIRT1 Signaling
Shreekrishna Lamichane1,2, Sang Hong Baek3, Yeon-Ju Kim4
1Convergence Stem Cell Research Center, Pusan National University, Yangsan, Republic of Korea.
Insights
MHY2233, a SIRT1 activator, combats cellular senescence in endothelial progenitor cells (EPCs). This antiaging compound enhances EPC function, offering potential for treating age-associated cardiovascular diseases (CVDs).
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Aging and Gerontology
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of mortality.
- Pharmacotherapies for CVDs often result in side effects and incomplete recovery.
- Stem cell therapy, particularly using endothelial progenitor cells (EPCs), shows promise for CVD treatment, but cellular senescence impairs EPC function.
Purpose of the Study:
- To investigate the effect of MHY2233, a novel SIRT1 activator, on cellular senescence in EPCs.
- To evaluate MHY2233's potential as a therapeutic agent for age-associated CVDs.
Main Methods:
- Assessed MHY2233's impact on SIRT1 expression and deacetylase activity.
- Measured changes in senescence biomarkers (p53, p16, p21) and SA-β-gal positive cells.
- Evaluated MHY2233's effects on senescence-associated secretory phenotypes (SASPs) and oxidative stress markers (ROS) in EPCs.
- Assessed the functional recovery of senescent EPCs, including angiogenesis, proliferation, and migration.
Main Results:
- MHY2233 increased SIRT1 expression and activity, reducing senescence biomarkers and SA-β-gal positive cells.
- MHY2233 decreased SASP factors (IL-6, IL-8, IL-1α, IL-1β) and cellular ROS levels.
- Treatment with MHY2233 enhanced angiogenesis, proliferation, and migration of senescent EPCs, improving cell survival and function.
Conclusions:
- MHY2233 effectively reduces replicative and oxidative stress-induced senescence in EPCs.
- The compound MHY2233 demonstrates potential as a therapeutic agent for age-associated cardiovascular diseases by rejuvenating EPC function.
Abstract:
Cardiovascular diseases (CVDs) are a major cause of death worldwide. Due to the prevalence of many side effects and incomplete recovery from pharmacotherapies, stem cell therapy is being targeted for the treatment of CVDs. Among the different types of stem cells, endothelial progenitor cells (EPCs) have great potential. However, cellular replicative senescence decreases the proliferation, migration, and overall function of EPCs. Sirtuin 1 (SIRT1) has been mainly studied in the mammalian aging process. MHY2233 is a potent synthetic SIRT1 activator and a novel antiaging compound. We found that MHY2233 increased the expression of SIRT1, and its deacetylase activity thereby decreased expression of the cellular senescence biomarkers, p53, p16, and p21. In addition, MHY2233 decreased senescence-associated beta-galactosidase- (SA-β-gal-) positive cells and senescence-associated secretory phenotypes (SASPs), such as the secretion of interleukin- (IL-) 6, IL-8, IL-1α, and IL-1β. MHY2233 treatment protected senescent EPCs from oxidative stress by decreasing cellular reactive oxygen species (ROS) levels, thus enhancing cell survival and function. The angiogenesis, proliferation, and migration of senescent EPCs were enhanced by MHY2233 treatment. Thus, MHY2233 reduces replicative and oxidative stress-induced senescence in EPCs. Therefore, this novel antiaging compound MHY2233 might be considered a potent therapeutic agent for the treatment of age-associated CVDs.
Related Concept Videos
Replicative Cell Senescence
Chromosome Replication
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Cell-surface Signaling
What is Cell Signaling?
DNA Replication
Replication in Prokaryotes
DNA replication...

